Literature DB >> 1743254

Acute haemodynamic effects of i.v. nitrendipine in healthy subjects.

G Mikus1, C Zekorn, T Brecht, M Eichelbaum.   

Abstract

The haemodynamic effects of an i.v. infusion of 2 mg nitrendipine have been studied in six healthy volunteers. Nitrendipine significantly decreased the systolic (-8.3%) diastolic (-19.9%) and mean arterial (-11.6%) blood pressures and the peripheral vascular resistance (-57.8%), and significantly increased leg blood flow (+128%). Stroke volume did not change. Due to the increase in heart rate (+28.5%), the cardiac output (2.8.2%) rose significantly. The haemodynamic effects were closely related to the serum nitrendipine concentration. The sigmoidal Emax-model was appropriate to describe the data. Pronounced interindividual differences in the serum nitrendipine concentrations required to elicit 50% of the maximum haemodynamic effect (EC50) were observed. The EC50 for the increase in leg blood flow ranged from 2.9 to 30.9 ng/ml and for the reduction in peripheral vascular resistance from 2.1 to 25.7 ng/ml. Interindividual differences in EC50 values were less pronounced if based on unbound serum nitrendipine levels. The fraction of nitrendipine not bound to serum proteins showed a three-fold difference between subjects, with free fractions ranging from 0.011 to 0.036. The unbound EC50 values for the increase in leg blood flow varied between 0.06 and 0.44 ng/ml and for the reduction in peripheral vascular resistance from 0.07 to 0.35 ng/ml. Based on the serum concentrations associated with comparable haemodynamic effects nitrendipine was at least three-times more potent than nifedipine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1743254     DOI: 10.1007/BF00265899

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension.

Authors:  G Mikus; V Mast; C Fischer; C Machleidt; U Kuhlmann; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  Hemodynamic effects of calcium antagonists. Review.

Authors:  H U Lehmann; H Hochrein; E Witt; H W Mies
Journal:  Hypertension       Date:  1983 Jul-Aug       Impact factor: 10.190

Review 3.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

4.  Mode of antihypertensive action of nitrendipine.

Authors:  S Kazda; B Garthoff; G Luckhaus
Journal:  J Cardiovasc Pharmacol       Date:  1984       Impact factor: 3.105

5.  Nitrendipine and other calcium entry blockers (calcium antagonists) in hypertension.

Authors:  S Kazda; B Garthoff; A Knorr
Journal:  Fed Proc       Date:  1983-02

6.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

7.  [Antihypertensive effect of nitrendipine, nifedipine and acebutolol and their combination on resting and exercise blood pressure in hypertensive patients].

Authors:  I W Franz; D Wiewel
Journal:  Z Kardiol       Date:  1985-02

8.  Quantification of nitrendipine by stable isotope dilution and electron-capture negative ion chemical ionization.

Authors:  C Fischer; B Heuer; K Heuck; M Eichelbaum
Journal:  Biomed Environ Mass Spectrom       Date:  1986-12

9.  Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers.

Authors:  T J Walley; A M Heagerty; K L Woods; R F Bing; J E Pohl; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1987-06       Impact factor: 4.335

10.  Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.

Authors:  C H Kleinbloesem; J van Harten; J P Wilson; M Danhof; P van Brummelen; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1986-07       Impact factor: 6.875

View more
  1 in total

1.  A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers.

Authors:  P Francheteau; J L Steimer; H Merdjan; M Guerret; C Dubray
Journal:  J Pharmacokinet Biopharm       Date:  1993-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.